DCM Nouvelle Limited has informed the Exchange regarding Board meeting held on August 13, 2025.
DCMNVL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
DCM Nouvelle Limited's board approved unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended 30 June 2025), along with the limited review report from auditor Walker Chandiok & Co LLP. On a standalone basis, revenue from operations fell to ₹24,969 lakhs from ₹26,528 lakhs in Q1 FY25 (a decline of about 6% year-on-year), while profit after tax jumped sharply to ₹666 lakhs from ₹153 lakhs (over 4x growth). EPS rose to ₹3.87 from ₹0.52 a year ago. On a consolidated basis, the company reported a small profit of ₹160 lakhs versus a loss of ₹649 lakhs in Q1 FY25, though the chemicals subsidiary (DCM Nouvelle Specialty Chemicals) continued to post losses of about ₹510 lakhs. The board also approved the re-appointment of Walker Chandiok & Co LLP as statutory auditor for a second 5-year term, subject to shareholder approval. The auditor issued an unmodified review conclusion on both sets of results.
Strong profit growth despite a modest revenue dip suggests meaningful margin expansion, which is positive for shareholders. However, the chemicals arm remains a drag on consolidated earnings, so investors should track whether that segment turns around. The continued engagement of a reputable auditor supports governance stability.